OrbiMed raises $3bn to back global life science players

Positive

AI Analysis

Summary

OrbiMed has raised $3bn through a duo of funds to back global life science companies across biopharma, healthcare technology, diagnostics and medical devices.

Outcome Details

OrbiMed raised $3bn across two funds to invest in life science companies spanning biopharma, healthcare technology, diagnostics and medical devices.

Importance:4/10

Sentiment:

0.50

fundraisingventure capitallife sciencesbiopharmahealthcare technologydiagnosticsmedical devices

Related Companies

$HR $MDCE $GBCMD

Read the original article

Published by Pharmaceutical Technology on October 16, 2026 10:59 AM

Read Original